FEBUXOSTAT 40mg. IP

A novel inhibitor of xanthine oxidase that decreases blood uric acid made by the body, prevents damage to the joints, and treats gout. (Susan P Bruce, 2006) Effective in lowering uric acid to less than 6.0 mg/dL. (Tayar JH, 2012) A well-tolerated medicine in long-term treatment in patients experiencing intolerance to allopurinol. (Tomlinson, 2008) Rapidly and sustainably reduces serum uric acid by 25% to 70%. (H Ralph Schumacher Jr, 2005) Approved by the U.S. Food and Drug Administration for chronic management of hyperuricemia in the gout population. (Bryan L Love, 2010) A promising alternative to allopurinol for the treatment of gout and hyperuricemia. (Kuang-Hui Yu, 2007) Provides more potent and longer-lasting hypouricemic action than allopurinol. (PÁL PACHER, 2006) A safe and efficacious candidate than allopurinol due to its more potent hypouricemic effect. (Naoyuki Kamatani, 2011)